{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:02:36Z","timestamp":1793318556436,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006564","name":"Yozgat Bozok \u00dcniversitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijgc.2026.104697","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:04:10Z","timestamp":1776143050000},"page":"104697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The effects of immune checkpoint inhibitors and targeted therapies on female fertility and ovarian function: a systematic review"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4200-2659","authenticated-orcid":false,"given":"\u00c7a\u011flayan","family":"Ate\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1137-8650","authenticated-orcid":false,"given":"Berna","family":"Dilbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif G\u00f6knur","family":"Top\u00e7u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sel\u00e7uk","family":"Erk\u0131l\u0131n\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2026.104697_bib1","doi-asserted-by":"crossref","DOI":"10.2196\/12593","article-title":"Oncofertility decision support resources for women of reproductive age: systematic review","volume":"5","author":"Speller","year":"2019","journal-title":"JMIR Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104697_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1530\/REP-15-0163","article-title":"Oncofertility: a grand collaboration between reproductive medicine and oncology","volume":"150","author":"Woodruff","year":"2015","journal-title":"Reproduction"},{"key":"10.1016\/j.ijgc.2026.104697_bib3","first-page":"JGO.2016","article-title":"Survey of fertility preservation options available to patients with cancer around the globe","volume":"6","author":"Rashedi","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104697_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12885-018-4046-x","article-title":"Fertility preservation healthcare circuit and networks in cancer patients worldwide: what are the issues?","volume":"18","author":"Melan","year":"2018","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104697_bib5","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.3928\/19382359-20250910-01","article-title":"Beyond survival: addressing pediatric oncofertility risk, preservation methods, and care disparities","volume":"54","author":"Knopoff","year":"2025","journal-title":"Pediatr Ann"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104697_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cancers17020238","article-title":"Female oncofertility and immune checkpoint blockade in melanoma: where are we today?","volume":"17","author":"Lee","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104697_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104697_bib8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.ijgc.2026.104697_bib9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1055\/a-2562-8469","article-title":"Adjuvant targeted treatment of early hormone receptor-positive HER2-negative breast cancer: olaparib, abemaciclib or ribociclib - which one, how and for whom?","volume":"85","author":"Lukac","year":"2025","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104697_bib10","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/humrep\/deaa128","article-title":"The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation","volume":"35","author":"Winship","year":"2020","journal-title":"Hum Reprod"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104697_bib11","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/humrep\/deaf096","article-title":"Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies","volume":"40","author":"Arecco","year":"2025","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ijgc.2026.104697_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ijgc.2026.104697_bib13","unstructured":"Wells G., Shea B., O\u2019Connell D., et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. 2011. Available at: https:\/\/web.archive.org\/web\/20210716121605id_\/www3.med.unipmn.it\/dispense_ebm\/2009-2010\/Corso%20Perfezionamento%20EBM_Faggiano\/NOS_oxford.pdf. Accessed January 2, 2026."},{"key":"10.1016\/j.ijgc.2026.104697_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104697_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74087-9","article-title":"Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells","volume":"10","author":"Nakamura","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104697_bib16","doi-asserted-by":"crossref","first-page":"e1883","DOI":"10.1002\/onco.13941","article-title":"Outcomes of pregnancy during immunotherapy treatment for cancer: analysis of clinical trials sponsored by the National Cancer Institute","volume":"26","author":"Mittra","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104697_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-21-0209","article-title":"Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse","volume":"252","author":"Xu","year":"2021","journal-title":"J Endocrinol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104697_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104697_bib19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/s41591-024-02942-7","article-title":"Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses","volume":"30","author":"Friedman","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104697_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5625","article-title":"Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns","volume":"7","author":"Gougis","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104697_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103466","article-title":"Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B","volume":"9","author":"Marm\u00e9","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104697_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-025-07702-w","article-title":"Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy","volume":"212","author":"Perdrix","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104697_bib23","first-page":"420","article-title":"Reproductive impact of immune checkpoint inhibitor therapy in women with melanoma","volume":"6","author":"Rhodes","year":"2025","journal-title":"F S Rep"},{"key":"10.1016\/j.ijgc.2026.104697_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.reprotox.2025.109057","article-title":"Effects of PD-1 inhibitors on ovarian function-based on two-sample Mendelian randomization and visualization experimental validation","volume":"138","author":"Zheng","year":"2025","journal-title":"Reprod Toxicol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104697_bib25","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2026.104697_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104697_bib27","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/cancers14061420","article-title":"PARP inhibitors resistance: mechanisms and perspectives","volume":"14","author":"Giudice","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104697_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/biolre\/ioaf207","article-title":"DNA damage response signaling in oocytes from an oncofertility perspective","volume":"114","author":"Song","year":"2026","journal-title":"Biol Reprod"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104697_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101012","article-title":"Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers","volume":"14","author":"Janysek","year":"2021","journal-title":"Transl Oncol"},{"issue":"15","key":"10.1016\/j.ijgc.2026.104697_bib30","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1007\/s00018-018-2833-9","article-title":"The capacity of oocytes for DNA repair","volume":"75","author":"Stringer","year":"2018","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104697_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s43556-025-00385-1","article-title":"PARPs and PARP inhibitors: molecular mechanisms and clinical applications","volume":"6","author":"Wang","year":"2025","journal-title":"Mol Biomed"},{"issue":"15","key":"10.1016\/j.ijgc.2026.104697_bib32","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.3390\/ijms23158125","article-title":"The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review","volume":"23","author":"Lau","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104697_bib33","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1\u2212 or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104697_bib34","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.3390\/ijms22084203","article-title":"Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy","volume":"22","author":"Valabrega","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104697_bib35","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.32604\/or.2024.049743","article-title":"Pharmacological methods for ovarian function and fertility preservation in women with cancer: a literature review","volume":"32","author":"Cvetanovic","year":"2024","journal-title":"Oncol Res"},{"key":"10.1016\/j.ijgc.2026.104697_bib36","article-title":"Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104697_bib37","first-page":"411","article-title":"Immunotherapy and ovarian function: bridging reproductive health in oncology clinical trials","volume":"6","author":"Cromack","year":"2025","journal-title":"F S Rep"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104697_bib38","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.fertnstert.2005.04.060","article-title":"Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure","volume":"84","author":"Bakalov","year":"2005","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ijgc.2026.104697_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1658681","article-title":"The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges","volume":"16","author":"Abulajiang","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104697_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1634\/theoncologist.2019-0837","article-title":"It is time to talk about fertility and immunotherapy","volume":"25","author":"Duma","year":"2020","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104697_bib41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/OP.22.00469","article-title":"Minding the bathwater: fertility and reproductive toxicity in the age of immuno-oncology","volume":"18","author":"Kim","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ijgc.2026.104697_bib42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2022.11.005","article-title":"Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: cohort B of the TROPHIMMUN phase 2 trial","volume":"168","author":"You","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104697_bib43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000533972","article-title":"Immunotherapy for gestational trophoblastic neoplasia: a new paradigm","volume":"89","author":"Baas","year":"2024","journal-title":"Gynecol Obstet Investig"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104697_bib44","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3390\/cancers13123035","article-title":"Inhibition of CDK4\/6 as therapeutic approach for ovarian cancer patients: current evidences and future perspectives","volume":"13","author":"Dall\u2019Acqua","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104697_bib45","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.3390\/cancers15204923","article-title":"The role of cyclin-dependent kinases (CDK) 4\/6 in the ovarian tissue and the possible effects of their exogenous inhibition","volume":"15","author":"Scavone","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.ijgc.2026.104697_bib46","doi-asserted-by":"crossref","first-page":"15658","DOI":"10.18632\/oncotarget.24585","article-title":"CDK4\/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer","volume":"9","author":"Iyengar","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104697_bib47","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41419-023-05859-0","article-title":"Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:34:54Z","timestamp":1780306494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26002288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1048891X26002288"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104697","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of immune checkpoint inhibitors and targeted therapies on female fertility and ovarian function: a systematic review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104697"}}